Abstract
We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69–2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. The nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. The Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.
Acknowledgements
We acknowledge the support of American Journal Experts for English editing.
Author contributions
VH designed the study, collected and analyzed data, and wrote the paper; VU provided patient care and created the figures; GTK, NÖ, MK, GÖ, HD, SÇK, TA, EÜ, ÜK, AY, AA, OG, AK, FVO, Tİ, SK, İB, BŞK, MG, ZK, İOB, TP and SA provided patient care and contributed to the manuscript.
Disclosure statement
The authors declare no conflict of interest.